Clinical aspects of drug delivery to tumors

Journal of Controlled Release

Volumn 78, Issue 1-3, 2002, Pages 81-95

  Jessie, L S ^a   Jang, Seong H ^a   Wientjes, M Guill ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Bladder; Drug delivery; Drug transport; Organ

Indexed keywords

DOXORUBICIN; MITOMYCIN C; PACLITAXEL;

APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER MUSCLE; CAPILLARY; CELL DENSITY; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG PENETRATION; DRUG RELEASE; DRUG TRANSPORT; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; SUPERFICIAL CANCER;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; HUMANS; MITOMYCIN; NEOPLASMS; RESEARCH DESIGN; URINARY BLADDER NEOPLASMS;

EID: 0037122744     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(01)00488-6     Document Type: Article

References (29)

1. Adjuvant intravesicular pharmacotherapy for superficial bladder cancer
2. Cancer of the bladder
3. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: Interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party)
4. Intravesical therapy. A critical review
5. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients
6. Bladder tissue pharmacokinetics of intravesical taxol
7. Penetration of intravesical doxorubicin in human bladders
8. Penetration of mitomycin C in human bladder
9. Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine
10. Pharmacodynamics of mitomycin C in cultured human bladder tumors
11. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer
12. The International Mitomycin C Consortium, Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial
13. Distribution and activity of antineoplastic drugs in a tumor model
14. Slow penetration of anthracyclines into spheroids and tumors: A therapeutical advantage?
15. Relationship between the penetration, binding and average concentration of cytostatic drugs in human tumor spheroids
16. Penetration of substances into tumor tissue - A methodological study on cellular spheroids
17. Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids
18. Determinants of drug delivery and transport to solid tumors
19. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death
20. Determinants of paclitaxel penetration and accumulation in human solid tumor
21. Computational model of intracellular pharmacokinetics of paclitaxel
22. Time- and concentration-dependent penetration of doxorubicin in prostate tumors
23. Pharmacodynamics of immediate and delayed effects of paclitaxel: Role of slow apoptosis and intracellular drug retention
24. Characterisations of taxol-induced apoptosis and altered gene expression in human breast cancer cells
25. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol
26. Paclitaxel-induced apoptosis in MCF7 breast cancer cells
27. Pharmacodynamics of taxol in human head and neck tumors
28. Kinetics of hallmark biochemical changes in paclitaxel-induced apoptosis
29. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: Effect of treatment schedule